With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

Source: 
Endpoints
snippet: 

Mixed data from previous study readouts on its drug for short-term dry eye relief precipitated a rejection from the FDA, leaving Kala Pharmaceuticals’ fate in the hands of a third study. On Monday, that trial met its goals, setting up the Watertown, Massachusetts-based company to resubmit a marketing application in the second quarter.